Navigation Links
Danaher Corporation Announces Retirement of Executive Vice President Philip W. Knisely
Date:7/27/2009

WASHINGTON, July 27 /PRNewswire-FirstCall/ -- Danaher Corporation (NYSE: DHR) announced today that Philip W. Knisely, Executive Vice President, has decided to retire from Danaher effective as of the end of 2009.

Mr. Knisely has served as an Executive Vice President since joining Danaher in 2000.

"Phil has made tremendous contributions to the growth and evolution of the Danaher portfolio over the past nine years," said H. Lawrence Culp, Jr., President and Chief Executive Officer. "We have benefited greatly from Phil's leadership and he will be missed."

Danaher Corporation is a leading manufacturer of Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools and Components (www.danaher.com).

Statements in this release that are not strictly historical may be "forward-looking" statements. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These factors include, among other things, the risk factors described in our SEC filings, including our 2008 Annual Report on Form 10-K and Second Quarter 2009 Quarterly Report on Form 10-Q. These forward-looking statements speak only as of the date of this release and the Company does not assume any obligation to update any forward-looking statement.


'/>"/>
SOURCE Danaher Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Danaher Closes Subsequent Offering Period for Tektronix; Acquires Over 90% of TEK Shares
2. Danaher to Present at Citigroup Global Industrial Manufacturing Conference
3. Danaher Corporation Schedules First Quarter Conference Call
4. Danaher to Present at Goldman Sachs Global Industrials Conference
5. Danaher CEO Comments on Outlook
6. Danaher to Present at Barclays Capital Industrial Select Conference
7. Shareholders Challenge Danaher/Kerr to Phase Out Mercury Tooth Fillings
8. Danaher Announces Quarterly Dividend
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. Brooke Franchise Corporation Announces Selected July Results
11. MedThink Communications Retained by NanoBio Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Finn Mouseson”: ... take precedence in an average life. This mouse sets out on a journey that ... heart. “Finn Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe ... creation of published author, Brooks Rathell. , “We typically hear about the favor of ... financial favor of God. Not only does it exist, but it is meant for ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... the Society of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” ... for SPBA Members as it focused on best practices for third party administrators ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... 7, 2017 Caris Life Sciences, a ... the promise of precision medicine, today announced results ... of its molecular profiling approach in guiding therapeutic ... profiling plus (CGP+) with Caris Molecular Intelligence ® ... a molecular level, leading to more therapeutic options ...
Breaking Medicine Technology: